- Advanced search
- Immuno Portal
- Malaria Portal
Synonyms: AMG203  | MT203
Compound class: Antibody
Comment: Namilumab (AMG203, MT203) is an IgG1κ anti-macrophage colony-stimulating factor (GM-CSF; CSF2) monoclonal antibody . It is being developed by Micromet and Nycomed for the treatment of autoimmune and chronic inflammatory diseases.
Peptide sequences and structural information for this antibody are available from its IMGT/mAb-DB entry.
|No information available.|
|Summary of Clinical Use|
|Phase 2 evaluation in a 12 week study has demonstrated the clinical efficacy effected by inhibiting macrophage activity via targeting of GM-CSF in patients with rheumatoid arthritis .|
|Mechanism Of Action and Pharmacodynamic Effects|
|GM-CSF (CSF2) is a pro-inflammatory cytokine that is over-produced in many autoimmune and chronic inflammatory human diseases. Namilumab binds to this cytokine, neutralises its activity and mediates a reduction in inflammation in vitro and in preclinical in vivo models .|